World's Best Scientists 2026 revealed!
Award Badge
Biology and Biochemistry
Austria
2026
Award Badge
Medicine
Austria
2026

D-Index & Metrics

Biology and Biochemistry

D-Index
149
Citations
84051
World Ranking
188
National Ranking
1

Medicine

D-Index
149
Citations
84972
World Ranking
1199
National Ranking
5

Research.com Recognitions

  • 2026 - Research.com Biology and Biochemistry in Austria Leader Award
  • 2026 - Research.com Medicine in Austria Leader Award
  • 2025 - Research.com Biology and Biochemistry in Austria Leader Award
  • 2025 - Research.com Medicine in Austria Leader Award
  • 2023 - Research.com Biology and Biochemistry in Austria Leader Award
  • 2023 - Research.com Medicine in Austria Leader Award
  • 2022 - Research.com Biology and Biochemistry in Austria Leader Award
  • 2022 - Research.com Medicine in Austria Leader Award

Overview

Peter Valent is affiliated with the Medical University of Vienna in Austria and has a significant record of academic publications in the fields of medicine, immunology, and microbiology. Their research contributions span several subfields including immunology, hematology, molecular biology, rheumatology, and genetics.

The main topics of their work encompass mast cells and histamine, acute myeloid leukemia research, food allergy and anaphylaxis research, urticaria and related conditions, eosinophilic disorders and syndromes, asthma and respiratory diseases, and chronic myeloid leukemia treatments.

Valent's recent papers include:

  • "Molecular International Prognostic Scoring System for Myelodysplastic Syndromes," 2022, published in NEJM Evidence
  • "Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes," 2020, published in Nature Medicine
  • "Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement," 2021, published in European Heart Journal
  • "Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal," 2021, published in HemaSphere
  • "Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders," 2021, published in Cancer Discovery

The frequent co-authors who have collaborated extensively with Valent include:

  • Wolfgang R. Sperr
  • Michel Arock
  • Gregor Hoermann
  • Jason Gotlib
  • Karin Hartmann

Peter Valent regularly publishes in several prominent journals, with the highest number of contributions appearing in Blood, The Journal of Allergy and Clinical Immunology In Practice, Journal of Allergy and Clinical Immunology, International Journal of Molecular Sciences, and Leukemia.

Best Publications

  • Revised International Prognostic Scoring System for Myelodysplastic Syndromes

    Peter L. Greenberg;Heinz Tuechler;Julie Schanz;Guillermo Sanz

  • RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

    Johannes Zuber;Junwei Shi;Junwei Shi;Eric Wang;Amy R. Rappaport;Amy R. Rappaport

  • Diagnostic criteria and classification of mastocytosis: a consensus proposal

    Peter Valent;Hans P. Horny;Luis Escribano;B. Jack Longley

  • New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.

    Detlef Haase;Ulrich Germing;Julie Schanz;Michael Pfeilstöcker

  • Identification of profilin as a novel pollen allergen; IgE autoreactivity in sensitized individuals

    Rudolf Valenta;Michael Duchêne;Karin Pettenburger;Christian Sillaber

  • Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria.

    P. Valent;C. Akin;L. Escribano;M. Födinger

  • Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.

    Peter Valent;Amy D. Klion;Hans-Peter Horny;Florence Roufosse

  • Cancer stem cell definitions and terminology: the devil is in the details

    Peter Valent;Dominique Bonnet;Ruggero De Maria;Tsvee Lapidot

  • Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

    Uwe Rix;Oliver Hantschel;Gerhard Dürnberger;Lily L. Remsing Rix

  • Profilins constitute a novel family of functional plant pan-allergens.

    R Valenta;M Duchene;C Ebner;P Valent

  • Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts

    Peter Valent;Cem Akin;Dean D. Metcalfe

  • Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference

    Peter Valent;Hans-Peter Horny;John M. Bennett;Christa Fonatsch

  • Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal

    Peter Valent;Cem Akin;Michel Arock;Knut Brockow

  • New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

    Julie Schanz;Heinz Tüchler;Francesc Solé;Mar Mallo

  • Mast Cells, Mastocytosis, and Related Disorders

    Theoharis C. Theoharides;Peter Valent;Cem Akin

  • Simvastatin Reduces Expression of Cytokines Interleukin-6, Interleukin-8, and Monocyte Chemoattractant Protein-1 in Circulating Monocytes From Hypercholesterolemic Patients

    Abdolreza Rezaie-Majd;Thomas Maca;Robert A. Bucek;Peter Valent

  • Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture.

    Peter Valent;Eva Spanblochl;Wolfgang R. Sperr;Christian Sillaber

  • Transcriptional plasticity promotes primary and acquired resistance to BET inhibition

    Philipp Rathert;Mareike Roth;Tobias Neumann;Felix Muerdter

  • MDR1 Gene Expression and Treatment Outcome in Acute Myeloid Leukemia

    Robert Pirker;Josef Wallner;Klaus Geissler;Werner Linkesch

  • Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

    Elsa Bernard;Yasuhito Nannya;Robert P. Hasserjian;Sean M. Devlin

Frequent Co-Authors

Rudolf Valenta
Rudolf Valenta Medical University of Vienna
Wolfgang R. Sperr
Wolfgang R. Sperr Medical University of Vienna
Klaus Lechner
Klaus Lechner Medical University of Vienna
Andreas Reiter
Andreas Reiter Heidelberg University
Cem Akin
Cem Akin University of Michigan–Ann Arbor
Ulrich Germing
Ulrich Germing Heinrich Heine University Düsseldorf
Karin Hartmann
Karin Hartmann University Hospital of Basel
Peter Bettelheim
Peter Bettelheim University of Vienna
Susanne Vrtala
Susanne Vrtala Medical University of Vienna
Winfried F. Pickl
Winfried F. Pickl Medical University of Vienna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Peter Valent

Trending Scientists

Recently Published Articles